Solitumomab

Myosin Therapeutics Inc., a biotechnology company leveraging its innovative platform technology to identify new molecular entities capable of selectively targeting nanomotor proteins, announced today that it supplemented its National Institutes of Health (NIH) funding with a seed funding round to advance the company's lead programs on glioblastoma and stimulant use disorder. Myosin Therapeutics, Inc. (the "Company") is developing its lead compound, MT-125, to treat glioblastoma, which is a highly aggressive form of brain cancer with a 95% fatality rate and limited treatment options available. In early models, MT-125 has shown that it can simultaneously arrest cancer cell division and migration, and therefore could be a first-in-class therapy. The Company believes that this funding should allow it to reach IND filing for MT-125. Stimulant use disorder, which includes dependence on drugs such as methamphetamine and cocaine, affects millions of people worldwide, is associated with significant morbidity and mortality, and has no FDA-approved treatments. The Company believes that this capital infusion along with existing funding from the National Institute of Health should provide the funding needed to advance Myosin Therapeutics' other lead compound, MT-110, for stimulant use disorders through Phase 1 clinical trials. "We are excited to receive this funding, which will allow us to rapidly advance our first-in-class treatments for glioblastoma and stimulant use disorder, two devastating conditions that lack effective treatments," said Dr. Courtney Miller, co-founder of Myosin Therapeutics. "Our platform for targeting the largely untapped families of nanomotor proteins represents a unique and promising strategy for oncology, in particular." The seed funding round was led by Mint12 Pharma, LLC, with participation from the University of Florida Ventures, DeepWork Capital, and the Florida Opportunity Fund. Mint12 Pharma's Managing Partner, Dave Adams, said, "We are thrilled to partner with Myosin Therapeutics to develop innovative therapies for these two conditions that currently lack effective treatment. Myosin's nanomotor platform has tremendous potential and we look forward to seeing the company's progress in the coming years." About Myosin Therapeutics. Myosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of The Herbert Wertheim UF Scripps Institute (formerly Scripps Research, Florida) focused on develop therapies for central nervous system and oncology indications with a platform for targeting molecular nanomotor proteins. The company's lead programs for glioblastoma and stimulant use disorder target myosin motor proteins, which play a critical role in a wide range of cellular processes. Myosin Therapeutics was founded in 2020 by Drs. Courtney Miller, Patrick Griffin, and Theodore Kamenecka. To learn more about the company, please visit www.myosintherapeutics.com. Mint12 Pharma invests in new patented core pharmaceutical and biotech technologies that have the potential to address fast growing and underserved markets with no current FDA approved therapies by providing financing, placing new executive management to support existing scientific leadership, and governance oversight. Mint12 Pharma provides Seed and Series A financing to companies and is led by an experienced team of Pharma/Biotech operators and investing professionals. SOURCE Myosin Therapeutics Inc.

Clinically validated pH-sensitive nanomedicine platform allows for tumor specific delivery of protein therapeutics and increased tolerability SOUTHLAKE, Texas--(BUSINESS WIRE)-- OncoNano Medicine, Inc. today announced the presentations of positive preclinical data on the company’s ON-BOARD™ pH-activatable delivery platform at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, Massachusetts. The data presented at SITC 2022 demonstrated the capability of the ON-BOARD™ platform for effective encapsulation and improvement of the therapeutic index of a variety of therapeutic payloads, including bispecific T cell engagers (TCE) and a therapeutic cytokine – IL-2-Fc, using relevant animal models. The ON-BOARD™ platform is designed to protect oncology intervention payloads systemically and release them in the acidic tumor microenvironment, minimizing systemic exposure and toxicity. OncoNano’s lead clinical candidate, pegsitacianine, currently in Phase 2 clinical trials, is formulated with ON-BOARD™, and the clinical data has validated its pH-activated tumor specificity. In the two separate presentations, a variety of TCEs including solitomab, runimotamab and several TCEs with undisclosed targets as well as a human IL-2 fused with IgG Fc were encapsulated using the ON-BOARD™ platform. The data demonstrated that: ON-BOARD™ successfully encapsulated TCEs across a range of different targets and structural configurations without any protein engineering involved ON-BOARD™-encapsulated TCEs demonstrated rapid release and high pH specificity as well as pH-activated cytotoxicity against various cancer cell lines in vitro ON-BOARD™ encapsulation of an undisclosed TCE significantly improved its tolerability in vivo compared to the unencapsulated molecule and inhibited the growth of a poorly immunogenic “cold” tumor model with in-tumor payload activation confirmed by PD markers ON-BOARD™-encapsulated IL-2-Fc showed robust anti-tumor efficacy in both the "hot" MC38 and the "cold" B16F10 tumors and greatly suppressed systemic toxicity compared to unencapsulated IL-2-Fc “We were excited to share the positive data on the encapsulation of a variety of bispecific T cell engagers and a therapeutic cytokine and the significant improvement of therapeutic index without complicated protein engineering,” said Tian Zhao, PhD, Vice President of Research and Development at OncoNano. “We look forward to developing this technology for clinical translation with these types of payload molecules in the near future.” Presentation Overview Title: A Clinically Validated pH-Sensitive Nanomedicine Platform for Encapsulating Therapeutic Bispecific T Cell Engagers for Tumor Specific Delivery and Activation Date: November 10 – 11, 2022 Time: 9:00 am - 9:00 pm EST Location: Poster Hall, Boston Convention and Exhibition Center, Boston, MA Title: Ultra-pH Sensitive Nanoparticles Increase Therapeutic Index of IL-2-Fc Date: November 12, 2022 Time: 10:40 am – 10:50 am EST Location: Session 302: Thomas Waldmann Memorial Plenary Session: New Immunotherapies, Boston Convention and Exhibition Center, Boston, MA About OncoNano Medicine OncoNano Medicine is developing a new class of products that utilize principles of molecular cooperativity in their design to exploit pH as a biomarker to diagnose and treat cancer with high specificity. Our product candidates and interventions are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image guided surgery and a platform of immuno-oncology therapeutics that activate and guide the body’s immune system to target cancer. OncoNano’s lead development candidate is pegsitacianine, a novel fluorescent nanoprobe using the ON-BOARD™ platform, that is currently under study in Phase 2 clinical trials as a real-time surgical imaging agent for use in multiple cancer surgeries. ONM-501, OncoNano’s second development program, is a next generation STING (STimulator of INterferon Genes) agonist that is advancing towards a first in human trial in the first half of 2023. Pegsitacianine and ONM-501 have been supported by grants received from the Cancer Prevention Research Institute of Texas. Learn more at .